Literature DB >> 19459818

Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels.

L J Hickson, L T J Hickson1, Z M El-Zoghby, E C Lorenz, M D Stegall, A S Jaffe, F G Cosio.   

Abstract

Assessing cardiovascular (CV) risk pretransplant is imprecise. We sought to determine whether cardiac troponin T (cTnT) relates to patient survival posttransplant. The study includes 603 adults, recipients of kidney transplants. In addition to cTnT dobutamine stress echography and coronary angiography were done in 45% and 19% of the candidates respectively. During 28.4 +/- 12.9 months 5.6% of patients died or had a major cardiac event. cTnT levels were elevated (>0.01 ng/ml) in 56.2% of patients. Elevated cTnT related to reduced event-free survival (hazard ratio (HR) = 1.81, CI 1.33-2.45, p < 0.0001) whether those events occurred during the first year or beyond. This relationship was statistically independent of all other variables tested, including older age, reduced left ventricular ejection fraction (EF) and delayed graft function. cTnT levels allowed better definition of risk in patients with other CV risk factors. Thus, event-free survival was excellent in older individuals, patients with diabetes, low EF and those with preexisting heart disease if their cTnT levels were normal. However, elevated cTnT together with another CV risk factor(s) identified patient with very poor survival posttransplant. Pretransplant cTnT levels are strong and independent predictors of posttransplant survival. These results suggest that cTnT is quite helpful in CV risk stratification of kidney transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19459818     DOI: 10.1111/j.1600-6143.2009.02636.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  10 in total

Review 1.  Screening for cardiovascular disease before kidney transplantation.

Authors:  Sneha Palepu; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2015-12-24

2.  Troponin I levels and postoperative myocardial infarction following renal transplantation.

Authors:  G R Shroff; S K Akkina; M D Miedema; R Madlon-Kay; C A Herzog; B L Kasiske
Journal:  Am J Nephrol       Date:  2012-01-25       Impact factor: 3.754

Review 3.  Challenges and opportunities for stem cell therapy in patients with chronic kidney disease.

Authors:  LaTonya J Hickson; Alfonso Eirin; Lilach O Lerman
Journal:  Kidney Int       Date:  2016-01-26       Impact factor: 10.612

4.  Modest rates and wide variation in timely access to repeat kidney transplantation in the United States.

Authors:  Jesse D Schold; Joshua J Augustine; Anne M Huml; John O'Toole; John R Sedor; Emilio D Poggio
Journal:  Am J Transplant       Date:  2019-11-15       Impact factor: 8.086

5.  Troponin T as a Predictor of End-Stage Renal Disease and All-Cause Death in African Americans and Whites From Hypertensive Families.

Authors:  LaTonya J Hickson; Andrew D Rule; Kenneth R Butler; Gary L Schwartz; Allan S Jaffe; Adam C Bartley; Thomas H Mosley; Stephen T Turner
Journal:  Mayo Clin Proc       Date:  2015-10-19       Impact factor: 7.616

6.  Nationwide Survey of Post-Transplant Glomerular Diseases, Based on the Japan Renal Biopsy Registry (J-RBR).

Authors:  Joichi Usui; Kunihiro Yamagata; Michio Nagata; Akira Shimizu; Asami Takeda; Hitoshi Sugiyama; Hiroshi Sato; Hitoshi Yokoyama
Journal:  Ann Transplant       Date:  2021-05-14       Impact factor: 1.530

7.  Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates.

Authors:  Mira T Keddis; Ziad El-Zoghby; Bruce Kaplan; Jeffrey W Meeusen; Leslie J Donato; Fernando G Cosio; D Eric Steidley
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

8.  Co-Administration of Melatonin Effectively Enhances the Therapeutic Effects of Pioglitazone on Mesenchymal Stem Cells Undergoing Indoxyl Sulfate-Induced Senescence through Modulation of Cellular Prion Protein Expression.

Authors:  Yong Seok Han; Sang Min Kim; Jun Hee Lee; Sang Hun Lee
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

9.  Allogeneic adipose tissue-derived stem cells ELIXCYTE® in chronic kidney disease: A phase I study assessing safety and clinical feasibility.

Authors:  Cai-Mei Zheng; I-Jen Chiu; Yu-Wei Chen; Yung-Ho Hsu; Lie-Yee Hung; Mei-Yi Wu; Yuh-Feng Lin; Chia-Te Liao; Yi-Pei Hung; Chia-Chu Tsai; Yih-Giun Cherng; Mai-Szu Wu
Journal:  J Cell Mol Med       Date:  2022-04-12       Impact factor: 5.295

Review 10.  The effect of aspirin on kidney allograft outcomes; a short review to current studies.

Authors:  Wisit Cheungpasitporn; Charat Thongprayoon; Donald G Mitema; Michael A Mao; Ankit Sakhuja; Wonngarm Kittanamongkolchai; Maria L Gonzalez-Suarez; Stephen B Erickson
Journal:  J Nephropathol       Date:  2017-01-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.